Vemurafenib-induced toxic epidermal necrolysis: is it an emerging side effect of the drug?

Abstract

Vemurafenib, a selective inhibitor of the BRAF-kinase used in treatment of metastatic melanoma alone or in combinations,¹ is known to cause various adverse skin reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions, affecting more than 90% of patients.^1-2 Severe adverse reactions were observed in less than 1% of the patients in clinical trials.³ However, the increasing number of reported cases of vemurafenib-induced toxic epidermal necrolysis (TEN), a life-threatening severe cutaneous adverse reaction, is striking. ^4-8 We herein present another patient with vemurafenib-induced TEN.

This article is protected by copyright. All rights reserved.

http://ift.tt/2jFqHbh